Clinical Significance of ABCB1 Genotyping in Oncology

Overview

Journal J Oncol Pharm Pract

Publisher Sage Publications

Specialties Oncology
Pharmacy

Date 2009 Apr 30

PMID 19401306

Citations 23

Authors

Alma Hamidovic

Kristine Hahn

Jill Kolesar

Affiliations

Soon will be listed here.

Abstract

Background: P-glycoprotein (Pgp) is a drug efflux pump that transports natural products, including taxanes and other chemotherapeutic agents, from cells. Several frequent polymorphisms in ATP binding cassette gene B1 (ABCB1) may influence Pgp levels and drug efflux. The purpose of this review was to assess the clinical significance of ABCB1 polymorphisms in oncology.

Methods: Peer-reviewed studies were identified through a search of PubMed/MEDLINE (1990-2008) and the ASCO abstracts (2003-2008) database. Included studies described clinical trials where ABCB1 genotyping was performed in patients with cancer. Search terms included ABCB1, Pgp, docetaxel, paclitaxel, irinotecan, imatinib, and anticancer agent. Studies were excluded if the manuscript was not available in English.

Results: The influence of polymorphisms in ABCB1 2677G>T/A, 3435C>T, and 1236C>T and progression-free and overall survival in 309 patients from the Australian Ovarian Cancer Study treated with paclitaxel/carboplatin demonstrated that compared to homozygote GG carriers at 2677, women with the minor T/A alleles were significantly less likely to relapse following treatment. Other trials of ABCB1 genotyping in breast and prostate cancer patients receiving taxanes have shown inconsistent results. Pharmacokinetic studies where ABCB1 was genotyped and patients received irinotecan or imatinib have also shown inconsistent results.

Conclusion: A number of commercially available drugs are substrates for Pgp, and the ABCB1-variant genotypes are frequent and functionally significant, which may have future implications for drug dosing.

Citing Articles

Role of SLC7A11/xCT in Ovarian Cancer.

Fantone S, Piani F, Olivieri F, Rippo M, Sirico A, Di Simone N Int J Mol Sci. 2024; 25(1).

PMID: 38203758 PMC: 10779187. DOI: 10.3390/ijms25010587.

Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.

Guijosa A, Freyria A, Espinosa-Fernandez J, Estrada-Mena F, Armenta-Quiroga A, Ortega-Trevino M Clin Transl Sci. 2022; 15(10):2403-2436.

PMID: 35892315 PMC: 9579387. DOI: 10.1111/cts.13370.

Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia.

Barcenas-Lopez D, Mendiola-Soto D, Nunez-Enriquez J, Mejia-Arangure J, Hidalgo-Miranda A, Jimenez-Morales S Transl Oncol. 2020; 14(1):100978.

PMID: 33290991 PMC: 7720095. DOI: 10.1016/j.tranon.2020.100978.

Gal J, Milano G, Brest P, Ebran N, Gilhodes J, Llorca L Pharmaceuticals (Basel). 2020; 13(11).

PMID: 33238394 PMC: 7700430. DOI: 10.3390/ph13110414.

[Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia].

He Y, Zao X, Wei X Nan Fang Yi Ke Da Xue Xue Bao. 2020; 38(1):34-41.

PMID: 33177018 PMC: 6765618. DOI: 10.3969/j.issn.1673-4254.2018.01.06.

References

Sakaeda T, Nakamura T, Okumura K . Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003; 4(4):397-410. DOI: 10.1517/phgs.4.4.397.22747. View

Kim R, Leake B, Choo E, Dresser G, Kubba S, Schwarz U . Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001; 70(2):189-99. DOI: 10.1067/mcp.2001.117412. View

Fromm M . The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev. 2002; 54(10):1295-310. DOI: 10.1016/s0169-409x(02)00064-9. View

Li Y, Wang Y, Li Y, Yang L . MDR1 gene polymorphisms and clinical relevance. Yi Chuan Xue Bao. 2006; 33(2):93-104. DOI: 10.1016/S0379-4172(06)60027-9. View

Kerb R, Hoffmeyer S, Brinkmann U . ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics. 2001; 2(1):51-64. DOI: 10.1517/14622416.2.1.51. View

Wang R, Kuo C, Lien L, Lien E . Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther. 2003; 28(3):203-28. DOI: 10.1046/j.1365-2710.2003.00487.x. View

Nobili S, Landini I, Giglioni B, Mini E . Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006; 7(7):861-79. DOI: 10.2174/138945006777709593. View

Sissung T, Baum C, Deeken J, Price D, Aragon-Ching J, Steinberg S . ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res. 2008; 14(14):4543-9. PMC: 2723795. DOI: 10.1158/1078-0432.CCR-07-4230. View

Evans W, McLeod H . Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003; 348(6):538-49. DOI: 10.1056/NEJMra020526. View

10.

Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K . Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics. 2003; 13(12):741-57. DOI: 10.1097/00008571-200312000-00005. View

11.

Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S . Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet. 2004; 19(1):1-14. DOI: 10.2133/dmpk.19.1. View

12.

Johnatty S, Beesley J, Paul J, Fereday S, Spurdle A, Webb P . ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res. 2008; 14(17):5594-601. DOI: 10.1158/1078-0432.CCR-08-0606. View

13.

Schinkel A, Jonker J . Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003; 55(1):3-29. DOI: 10.1016/s0169-409x(02)00169-2. View

14.

Stouch T, Gudmundsson O . Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev. 2002; 54(3):315-28. DOI: 10.1016/s0169-409x(02)00006-6. View

15.

Chang H, Rha S, Jeung H, Im C, Ahn J, Kwon W . Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2008; 20(2):272-7. DOI: 10.1093/annonc/mdn624. View

16.

Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C . mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res. 2006; 12(3 Pt 1):854-9. DOI: 10.1158/1078-0432.CCR-05-0950. View

17.

Jeong H, Herskowitz I, Kroetz D, Rine J . Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet. 2007; 3(3):e39. PMC: 1817653. DOI: 10.1371/journal.pgen.0030039. View

18.

Chin J, Soffir R, Noonan K, Choi K, Roninson I . Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol. 1989; 9(9):3808-20. PMC: 362442. DOI: 10.1128/mcb.9.9.3808-3820.1989. View

19.

Marsh S, Paul J, King C, Gifford G, McLeod H, Brown R . Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol. 2007; 25(29):4528-35. DOI: 10.1200/JCO.2006.10.4752. View

20.

Mathijssen R, Marsh S, Karlsson M, Xie R, Baker S, Verweij J . Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res. 2003; 9(9):3246-53. View